Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
Netilmicin
ntl · netilyn · vectacin · sch20569 · netillin · nettacin · ntromycin · ntromicine
식별자 및 물리적 특성
| CAS No. | 56391-56-1 |
|---|---|
| 분자식 | C21H41N5O7 |
| 평균 분자량 | 475.6 g/mol |
| 단동위원소 질량 | 475.30059865 g/mol |
| SMILES | CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O |
| InChIKey | CIDUJQMULVCIBT-MQDUPKMGSA-N |
| PubChem CID | 441306 |
| ChEMBL | CHEMBL1572 |
| EC No. | 260-146-8 |
| DTXSID | DTXSID1048542 |
화학 및 물리적 성질
| XLogP | -4.2 |
|---|---|
| 극성 표면적 | 200 |
| 수소 결합 공여자 수 | 8 |
| 수소 결합 수용자 수 | 12 |
| 회전 가능 결합 수 | 8 |
| 무거운 원자 수 | 33 |
| 형식 전하 | 0 |
| 복잡도 | 673 |
| 의약품 | Pharmaceuticals -> AntibioticsPharmaceuticals -> Listed in ZINC15 |
| Human Drugs | Ophthalmological preparations > Anti-infective agents |
| Decomposition | When heated to decomposition it emits acrid smoke and irritating fumes. |
| Optical Rotation | Specific optical rotation: +164 deg at 26 °C/D (3 in water) |
| Collision Cross Section | 216.82 Ų [M+Na]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards] |
| 끓는 점 | 575.33°C (rough estimate) |
| 밀도 | 1.2404 (rough estimate) |
| 굴절률 | 1.7500 (estimate) |
| pKa(산도 계수) | 13.29±0.70(Predicted) |
안전 및 규제
| FDA 요건 | Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended21 U.S.C. 321-392). |
|---|---|
| 보관 조건 | Commercially available netilmicin sulfate injection should be stored at 2 - 30 °C. /Netilmicin sulfate/ |
| 처리 방법 | SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices. |
| 상호 작용 | Concurrent and/or sequential use of 2 or more aminoglycosides by any route or concurrent use of capreomycin with aminoglycosides should be avoided since the potential for ototoxicity, nephrotoxicity, and neuromuscular blockade may be increasedhearing loss may occur and may progress to deafness even after discontinuation of the drugloss of hearing may be reversible, but usually is permanentneuromuscular blockade may result in skeletal muscle weakness and respiratory depression or paralysis (apnea). Also, concurrent use of 2 or more aminoglycosides may result in reduced bacterial uptake of each one since the medications compete for the same uptake mechanism. /Aminoglycosides/Concurrent use of medications with neuromuscular blocking activity, including halogenated hydrocarbon inhalation anesthetics, opioid analgesics, and massive transfusions with citrate anticoagulated blood, with aminoglycosides should be carefully monitored since neuromuscular blockade may be enhanced, resulting in skeletal muscle weakness and respiratory depression or paralysis (apnea)caution is recommended when these medications and aminoglycosides are used concurrently during surgery or in the postoperative period, especially if there is a possibility of incomplete reversal of neuromuscular blockade postoperativelytreatment with anticholinesterase agents or calcium salts may help reverse the blockade. /Aminoglycosides/Vancomycin and aminoglycosides must often be administered concurrently in the prophylaxis of bacterial endocarditis, in the treatment of endocarditis caused by streptococci and Corynebacteria species, in the treatment of resistant staphylococcal infections, or in penicillin-allergic patientsappropriate monitoring will help to reduce the risk of nephrotoxicity or ototoxicityrenal function determinations, serum aminoglycoside and vancomycin concentrations, dosage reductions, and/or dosage interval adjustments, or alternate antibacterials, may be required. /Aminoglycosides/Concurrent or sequential use of these medications /nephrotoxic or ototoxic medications/ with aminoglycosides may increase the potential for ototoxicity or nephrotoxicityhearing loss may occur and may progress to deafness even after discontinuation of the drug and may be reversible, but usually is permanentserial audiometric function determinations may be required with concurrent or sequential use of other ototoxic antibacterialsrenal function determinations may be required. /Aminoglycosides/For more Interactions (Complete) data for NETILMICIN (9 total), please visit the HSDB record page. |
| Human Toxicity Excerpts | Poison by intravenous, intramuscular, and subcutaneous routes. Human systemic effects by intravenous route: changes to kidney, ureter, and bladder. |
| Drug Induced Liver Injury | Drug-Induced Liver Injury Severity and Toxicity (DILIst)NetilmicinDILI PositiveDOI:10.1016/j.drudis.2019.09.022 |
| 독성 | LD50 in mice (mg/kg): 40 i.v.125 i.p.175 s.c. (Miller) |
| 유해 물질 데이터 | 56391-56-1(Hazardous Substances Data) |
용도
개요
This is a semisynthetic derivative of sisomicin, which was developed by ethylation of the 1-N position of the deoxystreptamine ring of sisomicin . Clinically, netilmicin is used as a sulfate. Netilmicin has a similar in vitro antibacterial spectrum to that of gentamicin but, unlike sisomicin, it is active against a proportion of gentamicin-resistant Gram-negative bacilli. However, netilmicin is not active against as wide a range of gentamicin-resistant Gram-negative bacilli as amikacin. Nevertheless, it may be occasionally indicated as an alternative to amikacin for the treatment of infections caused by gentamicin-resistant but netilmicin-susceptible Gram-negative organisms. The following details apply only to netilmicin